Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Total Equity · Q3 FY2026 · quarter ended Sep 2026

Total equity rises 127.0% from a year ago

Total equity stood at $753.74M at the end of Q3 FY2026, up 127.0% from a year earlier and up 215.2% from the prior quarter. Over 3 fiscal years it compounded at -3.6% a year.

Context

  • Total equity amounted to 95.8% of total assets at the end of Q3 FY2026, up 4.3 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +127.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$753.74M+215.2% QoQ
Last fiscal yearDec 2025
$305.26M+85.3% YoY
Year agoSep 2025
$332M+127.0% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+127.0%——
1 year+85.3%——
3-year CAGR-3.6%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
305.26M USD
Year-over-year change
+85.3%

Total Equity vs competitors

How AMLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +127.0% is the 3rd highest of 10, against a peer median of -18.7%.
  • Total equity amounts to 95.8% of total assets for AMLX, versus a peer median of 86.8%.
AMLX Competitors
Total Equity for AMLX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PRAXPraxis Precision Medicines, Inc.Sep 2026$1.26B USD+266.7%+126.0%96.0%
DNLIDenali Therapeutics Inc.Jun 2026$835.18M USD-18.7%-0.9%72.1%
AMLXAmylyx Pharmaceuticals, Inc.Sep 2026$753.74M USD+127.0%-3.6%95.8%
IONSIonis Pharmaceuticals, Inc.Sep 2026$393.64M USD-36.3%-5.1%13.5%
PRTAProthena Corporation plcMar 2026$312.62M USD-28.6%-23.3%89.3%
AVXLAnavex Life Sciences Corp.Dec 2025$126.62M USD+14.2%-12.7%95.2%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$100.46M USD-12.3%-1.2%68.5%
PMNProMIS Neurosciences, Inc.Jun 2026$49.4M USD+13012.1%—87.1%
ACIUAC Immune S.A.Mar 2026CHF 31.53M CHF-66.7%-35.7%22.9%
CLNNClene Inc.Mar 2026-$18.81M USD-278.2%—86.8%
Peer median (excluding AMLX) —-18.7%-5.1%86.8%

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents50.19M62.53M170.2M77.39M226.65M
Short-term Investments45.93M284.42M201.16M99.11M90.33M
Net Receivables015.31M40.05M447K88K
Inventory09.77M38.32M00
Other Current Assets3.44M10.11M14.93M12.48M6.6M
Total Current Assets104.95M382.13M464.67M189.43M323.67M
Property, Plant & Equipment (Net)474K8.14M6.41M2.73M5.49M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets189K1.19M46.38M1.47M3.48M
Total Non-current Assets663K9.32M52.79M4.2M8.97M
Total Assets105.61M391.45M517.45M193.63M332.65M
Account Payables4.37M6.26M22.06M2.94M3.52M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.28M15.23M40.93M9.99M10.06M
Total Current Liabilities17.4M46.61M82.04M28.41M22.69M
Long-term Debt00004.7M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities239.39M0000
Total Non-current Liabilities239.39M4.24M1.98M463K4.7M
Total Liabilities256.78M50.85M84.02M28.87M27.39M
Common Stock1K7K7K7K11K
Retained Earnings(155.85M)(354.22M)(304.95M)(606.69M)(751.43M)
Accumulated OCI9K(86K)197K(92K)404K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(151.17M)340.61M433.43M164.77M305.26M
Total Debt06.28M4.24M1.98M5.96M
Net Debt(50.19M)(56.25M)(165.96M)(75.41M)(220.69M)

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.